Argus analyst John Staszak upgraded Kimberly-Clark Corporation (KMB) to a Buy rating with a $120 price target, citing better-than-expected Q3 earnings and plans to acquire Kenvue. The acquisition of Kenvue, which owns major consumer health brands, is expected to strengthen KMB's position in resilient product categories, making it an appealing value pick for long-term investors. Kimberly-Clark generates most of its revenue through direct sales to retailers and has a broad global footprint serving both consumer and professional markets.

<p>Argus 分析师 John Staszak 将金佰利公司（Kimberly-Clark Corporation，KMB）的评级上调至买入，目标价为 120 美元，理由是其第三季度业绩好于预期，并计划收购 Kenvue。收购拥有主要消费健康品牌的 Kenvue 预计将增强 KMB 在抗压产品类别中的地位，使其成为长期投资者的有吸引力的价值选择。金佰利大部分收入来自对零售商的直接销售，并在服务消费者和专业市场方面拥有广泛的全球布局</p>

分析师指出，Kimberly Clark (KMB) 在加深其消费者健康领域的布局后，前景更加乐观